前列腺癌中微卫星不稳定的患病率及免疫检查点阻断治疗反应分析
该病例系列研究前瞻性分析1346例前列腺癌患者的1551份肿瘤标本,其中1033例可评估微卫星不稳定性(MSI),32例(3.1%)为MSI-H/dMMR。11例MSI-H/dMMR去势抵抗性前列腺癌患者接受抗PD-1/PD-L1治疗,6例(54.5%)前列腺特异性抗原下降超过50%,4例有影像学反应。
要点
- 1033例可评估患者中32例(3.1%)为MSI-H/dMMR前列腺癌。
- 11例MSI-H/dMMR去势抵抗性前列腺癌接受抗PD-1/PD-L1治疗,6例(54.5%)PSA下降>50%。
- 32例MSI-H/dMMR患者中7例(21.9%)携带Lynch综合征相关基因致病性胚系突变。
核心结论
- MSI-H/dMMR分子表型在前列腺癌中不常见但具有治疗意义,且可在疾病演进过程中体细胞获得。
- 鉴于抗PD-1/PD-L1治疗可能带来持久反应,这些发现支持对所有晚期前列腺癌患者进行前瞻性肿瘤测序以筛查MSI-H/dMMR。
- 由于并非所有MSI-H/dMMR表型患者均应答,需进一步研究探索耐药机制。
研究设计与样本
- 病例系列研究,前瞻性分析2015年1月1日至2018年1月31日在纪念斯隆凯特琳癌症中心接受治疗的1346例前列腺癌患者的1551份肿瘤标本,采用靶向测序检测。
- 患者诊断为前列腺癌,在计划肿瘤活检或存档组织可用时同意进行肿瘤分子分析;随访至2018年5月31日报告临床结局。
- 1033例肿瘤质量满足MSIsensor分析的患者(平均[SD]年龄65.6[9.3]岁)纳入分析。
主要发现
- 1033例可评估患者中32例(3.1%)为MSI-H/dMMR前列腺癌;23例(2.2%)MSIsensor评分高,另9例评分不确定但存在dMMR证据。
- 32例MSI-H/dMMR患者中7例(21.9%)携带Lynch综合征相关基因的致病性胚系突变。
- 6例患者有超过1个肿瘤 analyzed,其中2例在疾病后期出现获得性MSI-H表型。
- 11例MSI-H/dMMR去势抵抗性前列腺癌患者接受抗PD-1/PD-L1治疗,6例(54.5%)前列腺特异性抗原下降超过50%,其中4例有影像学反应。
- 截至2018年5月,6例应答者中5例(占全部11例的45.5%)仍在接受治疗,最长持续89周。
关键数值与推荐
- MSI-H/dMMR前列腺癌患病率:1033例中32例(3.1%)。
- MSIsensor高分肿瘤:1033例中23例(2.2%)。
- Lynch综合征相关基因致病性胚系突变:32例MSI-H/dMMR患者中7例(21.9%)。
- 抗PD-1/PD-L1治疗PSA下降>50%:11例中6例(54.5%)。
- 持续治疗:6例应答者中5例(全部11例的45.5%)仍在治疗,最长89周。
临床怎么用
- 作者认为,这些发现支持对所有晚期前列腺癌患者进行前瞻性肿瘤测序以筛查MSI-H/dMMR。
- 作者指出,由于并非所有MSI-H/dMMR表型患者均应答,需进一步研究探索耐药机制。
局限性
- 由于并非所有MSI-H/dMMR表型患者均应答,需进一步研究探索耐药机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The anti-programmed cell death protein 1 (PD-1) antibody pembrolizumab is approved by the US Food and Drug Administration for the treatment of microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors, but the prevalence of MSI-H/dMMR prostate cancer and the clinical utility of immune checkpoint blockade in this disease subset are unknown. OBJECTIVE: To define the prevalence of MSI-H/dMMR prostate cancer and the clinical benefit of anti-PD-1/programmed cell death 1 ligand 1 (PD-L1) therapy in this molecularly defined population. DESIGN, SETTING, AND PARTICIPANTS: In this case series, 1551 tumors from 1346 patients with prostate cancer undergoing treatment at Memorial Sloan Kettering Cancer Center were prospectively analyzed using a targeted sequencing assay from January 1, 2015, through January 31, 2018. Patients had a diagnosis of prostate cancer and consented to tumor molecular profiling when a tumor biopsy was planned or archival tissue was available. For each patient, clinical outcomes were reported, with follow-up until May 31, 2018. MAIN OUTCOMES AND MEASURES: Tumor mutation burden and MSIsensor score, a quantitative measure of MSI, were calculated. Mutational signature analysis and immunohistochemistry for MMR protein expression were performed in select cases. RESULTS: Among the 1033 patients who had adequate tumor quality for MSIsensor analysis (mean [SD] age, 65.6 [9.3] years), 32 (3.1%) had MSI-H/dMMR prostate cancer. Twenty-three of 1033 patients (2.2%) had tumors with high MSIsensor scores, and an additional 9 had indeterminate scores with evidence of dMMR. Seven of the 32 MSI-H/dMMR patients (21.9%) had a pathogenic germline mutation in a Lynch syndrome-associated gene. Six patients had more than 1 tumor analyzed, 2 of whom displayed an acquired MSI-H phenotype later in their disease course. Eleven patients with MSI-H/dMMR castration-resistant prostate cancer received anti-PD-1/PD-L1 therapy. Six of these (54.5%) had a greater than 50% decline in prostate-specific antigen levels, 4 of whom had radiographic responses. As of May 2018, 5 of the 6 responders (5 of 11 total [45.5%]) were still on therapy for as long as 89 weeks. CONCLUSIONS AND RELEVANCE: The MSI-H/dMMR molecular phenotype is uncommon yet therapeutically meaningful in prostate cancer and can be somatically acquired during disease evolution. Given the potential for durable responses to anti-PD-1/PD-L1 therapy, these findings support the use of prospective tumor sequencing to screen all patients with advanced prostate cancer for MSI-H/dMMR. Because not all patients with the MSI-H/dMMR phenotype respond, further studies should explore mechanisms of resistance.
引用
- Abida W, Cheng ML, Armenia J, et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA Oncol. 2019. PMID: 30589920. doi:10.1001/jamaoncol.2018.5801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。